Profile data is unavailable for this security.
About the company
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
- Revenue in USD (TTM)173.15m
- Net income in USD-394.24m
- Incorporated2000
- Employees796.00
- LocationPacific Biosciences of California Inc1305 O'brien DriveMENLO PARK 94025United StatesUSA
- Phone+1 (650) 521-8000
- Fax+1 (302) 636-5454
- Websitehttps://www.pacb.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVRx Inc | 47.26m | -58.48m | 328.04m | 200.00 | -- | 5.02 | -- | 6.94 | -2.71 | -2.71 | 2.19 | 2.69 | 0.4038 | 0.657 | 6.14 | 236,275.00 | -49.96 | -- | -54.21 | -- | 84.16 | -- | -123.75 | -- | 10.23 | -17.04 | 0.4302 | -- | 74.89 | -- | 0.5528 | -- | -- | -- |
| Nano-X Imaging Ltd | 10.13m | -57.47m | 344.55m | 164.00 | -- | 1.97 | -- | 34.02 | -0.9974 | -0.9974 | 0.1755 | 2.99 | 0.0482 | -- | 6.89 | 61,756.10 | -27.33 | -30.98 | -29.96 | -35.10 | -81.80 | -- | -567.41 | -1,527.24 | 5.09 | -- | 0.0181 | -- | 15.47 | -- | 46.33 | -- | 114.35 | -- |
| MaxCyte Inc | 45.60m | -35.74m | 368.13m | 143.00 | -- | 1.72 | -- | 8.07 | -0.3420 | -0.3420 | 0.4368 | 2.03 | 0.177 | 0.5576 | 7.17 | 318,878.30 | -13.87 | -13.18 | -14.86 | -14.33 | 85.98 | 88.79 | -78.37 | -62.96 | 9.22 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| ZimVie Inc | 451.30m | -47.73m | 372.31m | 2.60k | -- | 0.9152 | -- | 0.825 | -1.77 | -13.16 | 16.60 | 14.74 | 0.394 | 1.14 | 4.04 | 173,575.00 | -4.17 | -- | -4.81 | -- | 63.18 | 65.51 | -10.58 | -8.73 | 1.38 | -0.6264 | 0.3514 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Tactile Systems Technology Inc | 285.05m | 15.45m | 373.39m | 992.00 | 24.20 | 1.80 | 16.86 | 1.31 | 0.643 | 0.643 | 11.91 | 8.66 | 0.9812 | 6.20 | 6.80 | 287,349.80 | 5.32 | 0.9015 | 6.20 | 1.09 | 51.44 | 49.10 | 5.42 | 0.8309 | 3.80 | -- | 0.1146 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
| Alpha Teknova Inc | 36.35m | -31.68m | 412.57m | 210.00 | -- | 4.73 | -- | 11.35 | -0.7366 | -0.7366 | 0.834 | 1.64 | 0.2770 | 3.12 | 7.44 | 173,081.00 | -24.14 | -- | -25.92 | -- | 17.71 | -- | -87.17 | -- | 3.94 | -75.86 | 0.133 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
| Quanterix Corp | 129.33m | -39.71m | 422.94m | 441.00 | -- | 1.26 | -- | 3.27 | -1.04 | -1.04 | 3.40 | 8.77 | 0.3078 | 2.37 | 4.60 | 293,265.30 | -9.45 | -15.96 | -10.30 | -17.66 | 57.42 | 52.79 | -30.71 | -53.79 | 8.99 | -- | 0.00 | -- | 15.96 | 26.60 | 66.56 | -- | 20.07 | -- |
| Semler Scientific Inc | 58.94m | 15.91m | 430.67m | 92.00 | 28.92 | 4.94 | 26.02 | 7.31 | 2.05 | 2.05 | 7.58 | 11.99 | 0.6868 | 17.20 | 9.33 | 640,619.60 | 18.54 | 38.83 | 20.37 | 44.41 | 88.05 | 90.22 | 27.00 | 32.58 | 3.09 | -- | 0.00 | -- | 20.28 | 25.98 | 43.69 | 32.64 | -0.3821 | -- |
| Pacific Biosciences of California Inc | 173.15m | -394.24m | 468.75m | 796.00 | -- | 1.04 | -- | 2.71 | -1.46 | -1.46 | 0.64 | 1.65 | 0.1034 | 1.97 | 5.78 | 217,521.40 | -23.55 | -16.19 | -25.40 | -17.81 | 23.81 | 37.35 | -227.69 | -136.21 | 8.64 | -21.87 | 0.6634 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Treace Medical Concepts Inc | 202.86m | -61.52m | 497.13m | 516.00 | -- | 4.74 | -- | 2.45 | -0.9924 | -0.9924 | 3.27 | 1.68 | 0.8951 | 1.08 | 8.25 | 393,141.50 | -27.15 | -- | -32.22 | -- | 80.61 | -- | -30.33 | -- | 2.98 | -- | 0.3366 | -- | 31.92 | -- | -15.68 | -- | -- | -- |
| SI-Bone Inc | 157.04m | -37.40m | 509.55m | 344.00 | -- | 3.08 | -- | 3.24 | -0.9108 | -0.9108 | 3.82 | 3.95 | 0.6859 | 1.46 | 7.00 | 456,497.10 | -16.34 | -27.88 | -18.08 | -30.94 | 77.70 | 85.03 | -23.82 | -51.09 | 7.22 | -- | 0.1799 | -- | 30.52 | 20.19 | 29.25 | -- | 52.62 | -- |
| Mesa Laboratories Inc | 228.38m | -245.65m | 535.48m | 736.00 | -- | 3.31 | -- | 2.34 | -45.57 | -45.57 | 42.13 | 29.79 | 0.4186 | 2.74 | 5.96 | 310,298.90 | -45.02 | -9.20 | -54.70 | -9.88 | 62.47 | 60.60 | -107.56 | -28.33 | 0.5106 | 1.35 | 0.5594 | -- | -1.32 | 15.95 | -27,438.28 | -- | 15.26 | 0.00 |
| Simulations Plus Inc | 70.01m | 9.95m | 553.45m | 243.00 | 56.35 | 3.03 | 35.43 | 7.91 | 0.4894 | 0.4894 | 3.45 | 9.10 | 0.3659 | -- | 5.55 | 288,119.30 | 5.20 | 6.10 | 5.55 | 6.45 | 61.63 | 74.01 | 14.22 | 18.97 | -- | -- | 0.00 | 45.64 | 17.52 | 15.56 | -0.0703 | 3.01 | 17.07 | 0.00 |
| Surmodics Inc | 126.08m | -11.54m | 558.84m | 376.00 | -- | 4.70 | -- | 4.43 | -0.8145 | -0.8145 | 8.90 | 8.33 | 0.6922 | 2.20 | 6.03 | -- | -6.34 | -3.99 | -7.22 | -4.66 | 73.81 | 80.25 | -9.15 | -6.26 | 3.22 | -4.22 | 0.1991 | -- | -4.91 | 4.73 | -651.43 | -- | -12.34 | -- |
| AxoGen Inc | 180.86m | -14.31m | 567.71m | 426.00 | -- | 5.71 | -- | 3.14 | -0.3302 | -0.3302 | 4.16 | 2.26 | 0.9356 | 1.65 | 7.55 | 424,544.60 | -7.40 | -13.92 | -8.49 | -15.84 | 76.13 | 79.74 | -7.91 | -20.28 | 2.47 | -1.50 | 0.3224 | -- | 14.74 | 13.63 | 24.98 | -- | 17.70 | -- |
| Standard Biotools Inc | 155.90m | -170.60m | 599.34m | 534.00 | -- | 1.22 | -- | 3.84 | -0.7091 | -0.7091 | 0.5579 | 1.31 | 0.3054 | 2.48 | 6.01 | 291,951.30 | -24.41 | -28.17 | -29.37 | -33.60 | 48.57 | 51.58 | -79.91 | -74.85 | 3.41 | -- | 0.1014 | -- | 8.57 | -1.20 | 60.73 | -- | 50.06 | -- |
Data as of Nov 21 2024. Currency figures normalised to Pacific Biosciences of California Inc's reporting currency: US Dollar USD
57.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 30 Sep 2024 | 33.41m | 12.26% |
| Madrone Advisors LLCas of 30 Sep 2024 | 23.39m | 8.58% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 20.48m | 7.52% |
| Edmond de Rothschild Asset Management (France) SAas of 30 Sep 2024 | 20.31m | 7.45% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 17.24m | 6.33% |
| Millennium Management LLCas of 04 Nov 2024 | 12.40m | 4.55% |
| Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 11.87m | 4.35% |
| Geode Capital Management LLCas of 30 Sep 2024 | 6.33m | 2.32% |
| Jackson Square Partners LLCas of 30 Sep 2024 | 6.30m | 2.31% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 6.28m | 2.30% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
